Draft:Nautilus Biotechnology

  1. Home
  2. Wiki
  • Comment: Many of the sources are press releases or research articles by people associated with the company. These are not suitable sources for establishing the notability of the company. Stuartyeates (talk) 23:22, 16 August 2025 (UTC)
  • Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. Narec51 (talk) 00:35, 16 August 2025 (UTC)


Nautilus Biotechnology
Company typePublic
Nasdaq: NAUT
IndustryBiotechnology
Founded2016; 9 years ago
FounderParag Mallick, Sujal Patel
HeadquartersSeattle, Washington
Websitenautilus.bio

Nautilus Biotechnology, Inc. is a biotechnology company developing a single-molecule proteomics platform.[1] The Nautilus Proteome Analysis Platform integrates machine learning and biochemistry to measure the proteome and its proteoforms.[2][3]

Nautilus was founded in 2016 by Parag Mallick and Sujal Patel, who serve as the company’s Chief Scientist and CEO, respectively.[4][5] With corporate headquarters in Seattle, Washington, and research headquarters in San Carlos, California, Nautilus became a publicly traded company in 2021 through a merger with special-purpose acquisition company ARYA Life Sciences Acquisition Corp. III.[1]

History

[edit]

Co-founders Parag Mallick and Sujal Patel met when Mallick, now an Associate Professor at Stanford University, was Director of Clinical Proteomics at Cedars-Sinai and a customer of Isilon Systems, where Patel was previously founder and CEO before Isilon was acquired by EMC Corporation.[6][7] They established Nautilus after Mallick approached Patel with his idea for a single-molecule proteomics technology.[8]

In 2020, the company raised $76 million in a Series B financing round.[9] The round was led by Vulcan Capital and included participation from Andreessen Horowitz, Madrona Venture Group, and others.[9]

The company received $345 million in additional funding through its public listing in 2021.[10]

Nautilus serves on the Human Proteome Organization’s Industrial Advisory Board.[11]

Partnerships

[edit]

In 2020, the company initiated a research collaboration with Genentech to engage a pilot study using Nautilus’ technology on a protein target selected by Genentech.[12]

The following year, Nautilus inked research collaborations with Amgen to investigate proteins and proteoforms of interest, and with The University of Texas MD Anderson Cancer Center to measure the quantity and patterns of post-translational modifications on specific oncology protein targets.[12]

In 2023, Nautilus began working with a small cohort of researchers, including scientists at the Buck Institute for Research on Aging, as part of its First Access Challenge for exploring some of the first research applications of its platform.[13]

The company signed an agreement with the Allen Institute in 2025 to study the connection between tau protein and neurodegenerative conditions such as Alzheimer's disease.[14]

Technology

[edit]

The Nautilus Proteome Analysis Platform uses a method called “Iterative Mapping” to repeatedly interrogate billions of individual, intact, and uniformly distributed protein molecules deposited on massive flow cells.[3][15] The platform applies probes that either bind short sequences shared across proteins or bind to a specific protein and its possible modifications.[15][16] Machine learning algorithms decode the resulting binding patterns to identify the protein molecule in broadscale proteomics analyses or the individual proteoform in targeted studies.[3][15]

The Proteome Analysis Platform provides a list of protein or proteoform identities and abundances.[15] Identification at the single-molecule level enables the quantification of proteins or proteoforms in a sample by counting molecules of the same species.[3]

The technology differs from traditional approaches to protein measurement such as mass spectrometry in that it analyzes intact proteins at the single-molecule level rather than protein fragments and identifies lower-abundance proteoforms.[17][18]

In 2025, the company published a preprint describing the platform's ability to analyze proteoforms of the tau protein, which is associated with cognitive decline in Alzheimer's disease.[17][19]

[edit]
  • James Joly, et al. Development of a method for large-scale single-molecule analysis of tau proteoforms. bioRxiv(2025). doi:10.1101/2025.06.26.660445
  • Jarrett D. Egertson, et al. A theoretical framework for proteome-scale single-molecule protein identification using multi-affinity protein binding reagents. bioRxiv(2021). doi:10.1101/2021.10.11.463967
  • Tural Aksel, et al. High-density and scalable protein arrays for single-molecule proteomic studies. bioRxiv(2022). doi:10.1101/2022.05.02.490328

References

[edit]
  1. ^ a b Cumbers, John. "New Technology Could Unlock The Secrets Of Every Protein In The Body". Forbes. Retrieved 2025-09-12.
  2. ^ Coddington, Molly (2024-12-20). "When Science and Magic Collide in Proteomics". Technology Networks. Retrieved 2025-08-11.
  3. ^ a b c d Dutton, Gail (2023-11-27). "Proteomics Platform Reduces Quantification to Counting". Genetic Engineering and Biotechnology News. Retrieved 2025-08-11.
  4. ^ "Meet the man who combines science, technology and magic to understand proteins". Marketplace. 2024-06-18. Retrieved 2025-08-11.
  5. ^ "Biotech's Race for Drug Development". Bloomberg. 2021-07-07. Retrieved 2025-08-11.
  6. ^ "Parag Mallick". Stanford University. Retrieved 2025-08-11.
  7. ^ Philippidis, Alex (2021-09-30). "From IT to Biotech: Sujal Patel Discusses the Promise of the Proteome on "Close to the Edge"". GEN - Genetic Engineering and Biotechnology News. Retrieved 2025-09-12.
  8. ^ Schubert, Charlotte (2021-06-10). "Sujal Patel-led Nautilus Biotechnology goes public as it tackles ambitious plan to analyze proteins". GeekWire. Retrieved 2025-08-11.
  9. ^ a b Idrus, Amirah Al (2020-05-21). "Nautilus emerges with $76M to become the 'Illumina of proteomics' | Fierce Biotech". Fierce Biotech. Retrieved 2025-09-12.
  10. ^ Pasricha, Akash (2021-08-01). "Seattle biotech startup aims for 'new paradigm' in medicine by parsing proteins". The Seattle Times. Retrieved 2025-08-11.
  11. ^ "2025 IAB Companies and Representatives". Human Proteome Organization (HUPO). Retrieved 2025-08-11.
  12. ^ a b Borfitz, Deborah; Gloss, Stan (2021-12-15). "Nautilus Biotechnology Taking Protein Analysis To The Single-Molecule Level". Bio-IT World. Retrieved 2025-08-11.
  13. ^ Bonislawski, Adam (2023-04-12). "Nautilus Biotechnology Early-Access Users Exploring Platform's Discovery Proteomics Potential". GenomeWeb. Retrieved 2025-08-11.
  14. ^ Coddington, Molly (2025-09-04). "New Partnership Will Probe the Connection Between Tau Protein and Alzheimer's". Technology Networks. Retrieved 2025-09-12.
  15. ^ a b c d "The Next Generation of Proteome Analysis". The Scientist. 2025-07-08. Retrieved 2025-09-12.
  16. ^ Oldach, Laurel (2021-09-21). "Nautilus founder unspirals a new approach to proteomics". American Society for Biochemistry and Molecular Biology (ASBMB) Today. Retrieved 2025-09-12.
  17. ^ a b Marx, Vivien (2025-08-06). "Is single-molecule protein sequencing here yet?". Nature Methods. 22 (8): 1623–1628. doi:10.1038/s41592-025-02767-3. ISSN 1548-7091. PMID 40770569.
  18. ^ Bonislawski, Adam (2024-12-04). "Nautilus Proteomics Platform Could Bring New Depth to Proteoform Analyses". GenomeWeb. Retrieved 2025-08-11.
  19. ^ Joly, J.; Budamagunta, V.; Zhang, Z.; Nortman, B.; Jouzi, M.; Bhatnagar, R.; Egertson, J. D.; Flaster, M. E.; Grothe, R. (2025-07-21), "Large-scale single-molecule analysis of tau proteoforms", bioRxiv : The Preprint Server for Biology, bioRxiv, doi:10.1101/2025.06.26.660445, PMC 12262352, PMID 40667364, retrieved 2025-09-12